scholarly journals Long-term impact of dry eye symptoms on vision-related quality of life after phacoemulsification surgery

2018 ◽  
Vol 39 (2) ◽  
pp. 419-429 ◽  
Author(s):  
Wenwen Xue ◽  
Ming-ming Zhu ◽  
Bi-jun Zhu ◽  
Jian-nan Huang ◽  
Qian Sun ◽  
...  
2016 ◽  
Vol 39 (14) ◽  
pp. 1435-1440 ◽  
Author(s):  
Liesbet De Wit ◽  
Peter Theuns ◽  
Eddy Dejaeger ◽  
Stefanie Devos ◽  
Andreas R. Gantenbein ◽  
...  

2019 ◽  
Vol 8 (7) ◽  
pp. 1076 ◽  
Author(s):  
Aubrey R Tirpack ◽  
Elizabeth Vanner ◽  
James M Parrish ◽  
Anat Galor ◽  
Hong-Uyen Hua ◽  
...  

Dry eye and glaucoma are two frequently encountered ocular conditions, which can lead to substantial morbidity and decreased quality of life. Patients on topical glaucoma medications are known to be at greater risk for ocular surface symptoms. Veterans seen in the eye clinics at the Miami Veterans Affairs Hospital from January to July 2016 completed surveys assessing dry eye and ocular pain symptoms, including the five item Dry Eye Questionnaire (DEQ5). A total of 62 patients with glaucoma completed the survey. Of those, 52 were on glaucoma medications at the time of the survey, with the majority requiring more than one medication to control intraocular pressure. The frequency of mild or greater dry eye symptoms (defined as DEQ5 >6) tended to increase with increasing medication burden, and patients on brimonidine were more likely to report a DEQ5 >6. Patients on three or more glaucoma medications were more likely to report symptoms of shooting pain, dryness, and itchiness. Patients using timolol were more likely to report throbbing and pain by light, while those on latanoprost reported stinging. Our data support an association between increasing number of glaucoma medications and worsening of dry eye symptoms. Patient and medication-associated symptoms can be used to tailor individual medication regimens.


Author(s):  
Zhi Ven Fong ◽  
Yurie Sekigami ◽  
Motaz Qadan ◽  
Carlos Fernandez-del Castillo ◽  
Andrew L. Warshaw ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 900
Author(s):  
Diana C. Sanchez-Ramirez ◽  
Kaylene Normand ◽  
Yang Zhaoyun ◽  
Rodrigo Torres-Castro

Background: The long-term impact of COVID-19 is still unknown. This study aimed to explore post COVID-19 effects on patients chest computed tomography (CT), lung function, respiratory symptoms, fatigue, functional capacity, health-related quality of life (HRQoL), and the ability to return to work beyond 3 months post infection. Methods: A systematic search was performed on PubMed, Web of Science, and Ovid MEDLINE on 22 May 2021, to identify studies that reported persistent effects of COVID-19 beyond 3 months follow-up. Data on the proportion of patients who had the outcome were collected and analyzed using a one-group meta-analysis. Results: Data were extracted from 24 articles that presented information on a total of 5323 adults, post-infection, between 3 to 6 months after symptom onset or hospital discharge. The pooled prevalence of CT abnormalities was 59% (95% CI 44–73, I2 = 96%), abnormal lung function was 39% (95% CI 24–55, I2 = 94%), fatigue was 38% (95% CI 27–49, I2 = 98%), dyspnea was 32% (95% CI 24–40, I2 = 98%), chest paint/tightness was 16% (95% CI 12–21, I2 = 94%), and cough was 13%, (95% CI 9–17, I2 = 94%). Decreased functional capacity and HRQoL were found in 36% (95% CI 22–49, I2 = 97%) and 52% (95% CI 33–71, I2 = 94%), respectively. On average, 8 out of 10 of the patients had returned to work or reported no work impairment. Conclusion: Post-COVID-19 patients may experience persistent respiratory symptoms, fatigue, decreased functional capacity and decreased quality of life up to 6 months after infection. Further studies are needed to establish the extent to which post-COVID-19 effects continue beyond 6 months, how they interact with each other, and to clarify their causes and their effective management.


Sign in / Sign up

Export Citation Format

Share Document